Korten A G, ter Berg H J, Spincemaille G H, van der Laan R T, Van de Wel A M
Department of Neurology, Maaslandziekenhuis, Sittard, The Netherlands.
J Neurol Neurosurg Psychiatry. 1998 Jul;65(1):88-92. doi: 10.1136/jnnp.65.1.88.
The available data in the literature (177 cases), two current clinical patients, and cases which occurred in The Netherlands (13) were reviewed concerning the clinical presentation, pathological features, radiological data, and treatment options of chondrosarcoma of the cranial base. The mean age of patients was 37 years, the male/female ratio 1:1.1. The most frequent complaints were diplopia with oculomotor disorders (51%), headache (31%), and decreased hearing, dizziness, and tinnitus with statoacusticus dysfunction (21%). The mean duration of symptoms before diagnosis was 27 months. The chondrosarcomas were located in the petrosal bone in 37% (47 cases), in the occipital bone and clivus in 23% (30 cases), in the sphenoid bone in 20% (25 cases) and to a lesser extent in frontal, ethmoidal, and parietal bones (14%). In 6% (eight cases) the primary location was in dural tissue. Radiological examinations showed bone destruction and variable calcification (CT), involvement of neuronal and vascular structures (MRI), and mostly hypovascularity on angiography. On histological examination 51% of tumours were classified as grade I, 11% grade II, 30% mesenchymal, and 8% myxoid. The mesenchymal type was the most malignant as illustrated by a strong tendency to intradural and cerebral growth and possibly occurrence in younger age groups. The treatment of choice until recently was surgery because of the critical location and local aggressive nature. Regrowth of tumour after surgery occurred in 53% of the patients (average after 32 months). Charged particle irradiation gave a five year survival of 83-94% and a local control rate of 78%-91%. Both in surgery and radiotherapy there is treatment related morbidity and mortality that should be considered when offering these therapies. Recent promising results imply that charged particle radiotherapy, in combination with surgery, may be the therapeutical choice of the future.
我们回顾了文献中的现有数据(177例)、两名当前临床患者以及荷兰发生的病例(13例),内容涉及颅底软骨肉瘤的临床表现、病理特征、放射学数据和治疗选择。患者的平均年龄为37岁,男女比例为1:1.1。最常见的症状是伴有动眼神经障碍的复视(51%)、头痛(31%)以及伴有听觉功能障碍的听力下降、头晕和耳鸣(21%)。诊断前症状的平均持续时间为27个月。软骨肉瘤位于岩骨的占37%(47例),位于枕骨和斜坡的占23%(30例),位于蝶骨的占20%(25例),位于额骨、筛骨和顶骨的比例较小(14%)。6%(8例)的原发部位在硬脑膜组织。放射学检查显示骨质破坏和不同程度的钙化(CT)、神经和血管结构受累(MRI),血管造影显示大多为血管减少。组织学检查显示,51%的肿瘤被分类为I级,11%为II级,30%为间充质型,8%为黏液型。间充质型是最恶性的类型,表现为强烈的向硬膜内和脑内生长倾向,且可能发生在较年轻的年龄组。由于肿瘤位置关键且具有局部侵袭性,直到最近手术仍是首选治疗方法。53%的患者术后肿瘤复发(平均在32个月后)。带电粒子放疗的5年生存率为83% - 94%,局部控制率为78% - 91%。手术和放疗都存在与治疗相关的发病率和死亡率,在提供这些治疗时应予以考虑。近期令人鼓舞的结果表明,带电粒子放疗联合手术可能是未来的治疗选择。